2023 Targeted Therapies of Lung Cancer Meeting (Poster)-P1.14. Differentiating Ensartinib from Lorlatinib and Alectinib for First Line Use in an ALK+ Non-Small Cell Lung Cancer Preclinical Model (ResCu)

P1.14. Differentiating Ensartinib from Lorlatinib and Alectinib for First Line Use in an ALK+ Non-Small Cell Lung Cancer Preclinical Model (ResCu)

Pdf Summary

Summary Not Available

Asset Subtitle

Christopher Bulow, ResistanceBio, United States

Meta Tag

Speaker Christopher Bulow, ResistanceBio, United States

Topic Poster Listing